摘要
目的:通过检测甲状腺乳头状癌(papillary thyroid carcinoma,PTC)患者血浆DLEU2的水平,分析其与临床病理参数的关系,并探讨影响PTC及其淋巴结转移和临床分期的危险因素。方法:生物信息分析DLEU2在PTC组织和正常人群的水平。实时荧光定量聚合酶链反应(quantitative real-time PCR,qRT-PCR)检测22对PTC组织和癌旁组织以及89例PTC(PTC组)和36例正常人(对照组)血浆DLEU2的水平,分析89例PTC患者DLEU2与临床病理参数的关系。受试者工作特征(receiver operating characteristic,ROC)曲线分析DLEU2对PTC的诊断效能;二元Logistic回归分析影响PTC及其淋巴结转移和临床分期的因素。结果:生信结果显示512例PTC组织DLEU2表达量高于59例正常组织(P<0.001),ROC曲线下面积(area under the curve,AUC)为0.824,95%CI 0.755~0.893;22对PTC和癌旁组织qRT-PCR验证显示,PTC组织DLEU2的表达量高于癌旁组织(P<0.01)。PTC患者血浆DLEU2水平高于对照组(P<0.001),且DLEU2的表达与淋巴结转移有关,差异具有统计学意义(P<0.05);ROC曲线分析显示当DLEU2的截断值为1.114时,诊断PTC的AUC为0.765,95%CI 0.668~0.862,灵敏度为61.6%,特异度为80.6%;PTC组DLEU2的截断值为1.868时,诊断淋巴结转移AUC为0.766,95%CI 0.657~0.876,灵敏度为69.6%,特异度为72.7%。二元Logistic回归分析显示:DLEU2高表达是PTC的危险因素(OR=4.178,95%CI 1.287~13.567,P<0.05),PTC患者TG水平高于正常人群TG水平(OR=1.002,95%CI 1.000~1.005,P<0.05),女性患PTC的风险增加(OR=6.016,95%CI 2.372~15.257,P<0.01);淋巴结转移的患者血浆DLEU2表达水平高于无淋巴结转移患者血浆DLEU2表达水平(OR=3.684,95%CI 1.204~11.266,P<0.05),淋巴结转移的患者中TMAb水平高于无淋巴结转移患者的TMAb水平(OR=1.005,95%CI 1.000~1.010,P<0.05);临床Ⅲ+Ⅳ期TG水平高于临床Ⅰ+Ⅱ期TG水平(OR=1.003,95%CI 1.000~1.006,P<0.05)。结论:血浆DLEU2在PTC以及淋巴结转移患者中高表达,甲状腺功能指标TMAb和TG是PTC淋巴结转移和临床分期的有效预测指标。
Objective:To investigate the relationship between plasma DLEU2(long non-coding RNA DLEU2)and clinicopathological parameters in papillary thyroid carcinoma(PTC)patients.The risk factors affecting PTC,lymph node metastasis and clinical stage were also discussed.Methods:The biological information of DLEU2 in PTC tissue and normal group was analyzed.DLEU2 levels of 22 pairs of PTC tissue and paracancer tissue and plasma DLEU2 levels of 89 cases of PTC(PTC group)and 36 cases of normal control group(control group)were detected by quantitative real-time PCR.The relationship between the clinicopathological characteristics of PTC patients and the expression of plasma DLEU2 levels was analyzed.The diagnostic efficiency of DLEU2 for PTC was analyzed by receiver operating characteristic(ROC)curve.The factors affecting PTC,lymph node metastasis and clinical staging were analyzed by binary Logistic regression.Results:Biological information showed that DLEU2 expression in 512 cases of PTC tissues was higher than that in 59 cases of normal tissues(P<0.001).Area under the curve(AUC)was 0.824,95%CI 0.755~0.893.The expression level of DLEU2 in 22 cases of PTC tissues was higher than that those paracancer tissues(P<0.01).The plasma DLEU2 level in PTC group was higher than that in control group(P<0.001),and DLEU2 expression was associated with lymph node metastasis,the difference was statistically significant(P<0.05).ROC curve showed that the cut-off value of DLEU2 was 1.114.The AUC of the diagnosis of PTC was 0.765,95%CI 0.668~0.862,the sensitivity was 61.6%,and the specificity was 80.6%.When the cut-off value of DLEU2 in the PTC group was 1.868,the AUC under the diagnosed lymph node metastasis curve was 0.766,95%CI 0.657~0.876,the sensitivity was 69.6%,and the specificity was 72.7%.Binary Logistic regression showed that the high expression of DLEU2 was a risk factor for PTC(OR=4.178,95%CI 1.287~13.567,P<0.05),and the TG level of PTC patients was higher than that of normal population(OR=1.002,95%CI 1.000~1.005,P<0.05).Women had an increased risk of PTC(OR=6.016,95%CI 2.372~15.257,P<0.01).The level of plasma DLEU2 expression in patients with lymph node metastasis was higher than that the level of plasma DLEU2 expression in patients without lymph node metastasis(OR=3.684,95%CI 1.204~11.266,P<0.05),and the TMAb level in patients with lymph node metastasis was higher than that in patients without lymph node metastasis(OR=1.005,95%CI 1.000~1.010,P<0.05).The level of TG in stage Ⅲ+Ⅳ was higher than that in stage Ⅰ+Ⅱ(OR=1.003,95%CI 1.000~1.006,P<0.05).Conclusion:Plasma DLEU2 is highly expressed in PTC and lymph node metastasis.Thyroid function indexes TMAb and TG are effective predictors of lymph node metastasis and clinical stage of PTC.
作者
王安洋
李超友
霍蓉花
赵如华
张赫
李敏
薛刚
吴靖芳
WANG Anyang;LI Chaoyou;HUO Ronghua;ZHAO Ruhua;ZHANG He;LI Min;XUE Gang;WU Jingfang(Zhangjiakou Key Laboratory of Thyroid Cancer Precision Diagnosis and Treatment,Hebei Zhangjiakou 075000,China;Department of Otolaryngology,Head and Neck Surgery,the First Affiliated Hospital,Hebei North University,Hebei Zhangjiakou 075000,China)
出处
《现代肿瘤医学》
CAS
北大核心
2023年第15期2840-2845,共6页
Journal of Modern Oncology
基金
河北北方学院2022年度校级重大课题(编号:H2022405034)。
作者简介
王安洋(1997-),女,河北人,硕士在读,主要从事甲状腺癌相关研究。E-mail:1106151883@qq.com;通信作者:薛刚(1968-),男,河北人,主任医师,主要从事头颈外科临床工作。E-mail:xgwjf@163.com。
